Evotec lends its R&D might to the multiple sclerosis cause – FierceCRO

Germany’s Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.

The hybrid research organization is on tap to help out with a German government-sponsored effort to look at three pathways of treating the inflammatory disease: cytokine regulation, neuroprotection and tolerance induction. Evotec will lend out its drug discovery platform, project-management capabilities and industry connections to each effort, hoping to identify new candidates that go beyond treating the effects of MS and get to the root of the disease.

The projects range in length from 18 months to three years, Evotec said, and carry a total budget of roughly $6.3 million.

For Evotec, which splits its business into the CRO-like EVT Execute and R&D-focused EVT Innovate, the three deals complement its core competency, Chief Scientific Officer Cord Dohrmann said.

Read more – FierceCRO